AVBP
Price:
$19.36
Market Cap:
$662.36M
ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pen...[Read more]
Industry
Biotechnology
IPO Date
2024-01-26
Stock Exchange
NASDAQ
Ticker
AVBP
According to ArriVent BioPharma, Inc. Common Stock’s latest financial reports and current stock price. The company's current PE Ratio is -7.56. This represents a change of 1.41% compared to the average of -7.45 of the last 4 quarters.
The mean historical PE Ratio of ArriVent BioPharma, Inc. Common Stock over the last ten years is -12.69. The current -7.56 PE Ratio has changed 5.86% with respect to the historical average. Over the past ten years (40 quarters), AVBP's PE Ratio was at its highest in in the March 2022 quarter at -0.87. The PE Ratio was at its lowest in in the December 2022 quarter at -16.04.
Average
-12.69
Median
-11.70
Minimum
-18.15
Maximum
-9.22
Discovering the peaks and valleys of ArriVent BioPharma, Inc. Common Stock PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 39.83%
Maximum Annual PE Ratio = -9.22
Minimum Annual Increase = -49.21%
Minimum Annual PE Ratio = -18.15
Year | PE Ratio | Change |
---|---|---|
2024 | -10.42 | 12.99% |
2023 | -9.22 | -49.21% |
2022 | -18.15 | 39.83% |
The current PE Ratio of ArriVent BioPharma, Inc. Common Stock (AVBP) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-12.59
5-year avg
-12.69
10-year avg
-12.69
ArriVent BioPharma, Inc. Common Stock’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ArriVent BioPharma, Inc. Common Stock using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ArriVent BioPharma, Inc. Common Stock or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ArriVent BioPharma, Inc. Common Stock's PE Ratio?
How is the PE Ratio calculated for ArriVent BioPharma, Inc. Common Stock (AVBP)?
What is the highest PE Ratio for ArriVent BioPharma, Inc. Common Stock (AVBP)?
What is the 3-year average PE Ratio for ArriVent BioPharma, Inc. Common Stock (AVBP)?
What is the 5-year average PE Ratio for ArriVent BioPharma, Inc. Common Stock (AVBP)?
How does the current PE Ratio for ArriVent BioPharma, Inc. Common Stock (AVBP) compare to its historical average?